Retatrutide vs Tirzepatide: Which Weight Loss Injection Is Right for You?

The GLP-1 weight loss landscape has changed dramatically in just the past two years. Tirzepatide — sold commercially as Mounjaro and Zepbound — became a household name after producing results that stunned the medical community. Now a newer molecule, retatrutide, is generating even more discussion after early clinical data showed it may outperform every weight loss drug that came before it.

At The Hydro Drip Bar, we offer both as compounded injectables at our Temecula, Mira Mesa (San Diego), and National City locations. Clients ask us every week: which one should I choose? The honest answer depends on your goals, your medical history, your tolerance for side effects, and your budget — and that's exactly what this guide breaks down.

How Each Injection Works

To understand the difference, you first need to understand the receptor pathways involved. Both drugs are injectable medications given as weekly subcutaneous shots, but they target different combinations of hormonal receptors in the gut and brain.

Tirzepatide — Dual GIP/GLP-1 Agonist

Tirzepatide activates two receptors simultaneously: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). GLP-1 suppresses appetite, slows gastric emptying, and improves blood sugar regulation. GIP complements GLP-1 by improving insulin sensitivity and potentially enhancing fat metabolism. The combination creates a stronger and more balanced effect than GLP-1 alone, which is why tirzepatide outperformed earlier single-agonist drugs like semaglutide in head-to-head comparisons.

Retatrutide — Triple GIP/GLP-1/Glucagon Agonist

Retatrutide adds a third receptor target: the glucagon receptor. Glucagon is a hormone that, at baseline, signals the liver to release glucose and promotes fat burning. By activating the glucagon receptor alongside GIP and GLP-1, retatrutide creates a broader metabolic effect — particularly accelerating fat oxidation and increasing energy expenditure beyond what appetite suppression alone achieves.

This triple mechanism is why early Phase 2 and Phase 3 trial data for retatrutide has generated so much attention. At the highest doses, retatrutide trial participants lost an average of approximately 24% of their body weight over 48 weeks — a figure that exceeded what tirzepatide produced in the SURMOUNT trials.

Results: What the Data Shows

Both medications produce meaningful, clinically significant weight loss when combined with lifestyle modifications. Here is how their trial results compare:

An important caveat: clinical trial results represent averages across large populations. Your individual results will depend on your starting weight, dietary habits, activity level, and how your body responds to the specific receptor pathways targeted by each drug. Some people respond exceptionally well to tirzepatide's dual pathway; others find the addition of the glucagon agonist in retatrutide makes a significant difference.

Side Effects and Tolerability

Both medications share a similar side effect profile — which makes sense given they operate through overlapping receptor mechanisms. The most common effects are gastrointestinal and are most pronounced during dose titration (the period when your dose is increasing).

• Nausea: Most common during the first 4–8 weeks as your body adjusts. Typically mild to moderate and diminishes over time.
• Reduced appetite: This is the intended effect, but it can feel dramatic early on. Eating smaller, more frequent meals helps manage it.
• Constipation or loose stools: GI motility changes are common with both. Hydration and fiber intake matter more than usual.
• Fatigue: Some clients experience mild fatigue in the first few weeks as their body adapts to reduced caloric intake and metabolic changes.
• Injection site reactions: Minor redness or soreness at the injection site — usually resolved within 24 hours.

Retatrutide's addition of glucagon receptor activity means it may produce slightly more nausea at equivalent doses compared to tirzepatide in some patients — particularly those who are more sensitive to glucagon pathway activation. This is one reason our medical team typically starts retatrutide at a conservative dose and titrates more gradually.

Cost Comparison at The Hydro Drip Bar

As compounded injectables, both medications are significantly more accessible in terms of cost than brand-name pharmacy versions of GLP-1 drugs like Zepbound or Mounjaro, which can cost $900–$1,400/month without insurance.

All programs are supervised by our Medical Director, Dr. Guillermo Castillo, Board Certified in Family Medicine, and administered by our team of licensed Registered Nurses (Ricky Sarmiento RN, BSN and Mary Grace Sarmiento RN, BSN). Medical oversight, dose adjustments, and ongoing monitoring are included in the program cost.

Who Should Choose Which?

The most important thing to understand: this is not a decision you should make based on a blog post alone. Our medical team at The Hydro Drip Bar conducts a thorough intake before starting any client on either medication — reviewing health history, current medications, goals, and body composition. The right choice for you is the one our provider recommends after that evaluation.

Start Your GLP-1 Program in Temecula or San Diego

The Hydro Drip Bar offers both Tirzepatide and Retatrutide programs at all four Southern California locations:

• Temecula: 27420 Jefferson Ave, Suite 101-A — GLP-1 Temecula program details
• Mira Mesa, San Diego: 8160 Mira Mesa Blvd, Suites 111 & 112 — GLP-1 Mira Mesa program details
• National City: 3030 Plaza Bonita Rd, Suite #118 — GLP-1 National City program details
• Escondido: 272 E Via Rancho Pkwy (Inside Glow and Beauty Medspa)

Walk-in consultations are welcome. You can also book your intake appointment online at any time through our booking portal or call us directly at (951) 319-2382.

For a comprehensive overview of the full medical weight loss program — including how GLP-1 therapy fits into a broader plan — visit our Medical Weight Loss Hub page.